Document Detail

Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center.
MedLine Citation:
PMID:  16452066     Owner:  NLM     Status:  MEDLINE    
PURPOSE: A cross-sectional study was performed during 2004 at a large HIV clinic in Spain to identify HIV-HCV coinfected individuals who might be candidates for HCV therapy. METHOD: Plasma HCV RNA levels were measured in 405 anti-HCV antibody positive patients. Spontaneous HCV clearance had occurred in 11.4%. Overall, 165 (40.1%) of HCV-HIV coinfected patients had already been exposed to interferon (IFN)-based therapies. Excluding those currently on treatment, the majority of them had either failed (64/142; 45.1%) or not completed therapy (25/142; 17.6%). Other 103 (25.4%) chronic HCV carriers refused treatment or were not considered as appropriate candidates, most often due to low CD4 counts or severe neuropsychiatric conditions. Treatment was deemed feasible and planned in the near future in 91 (22.5%) patients. Unfavorable HCV genotypes (1 and 4) were significantly more frequent in this group of individuals ready for HCV treatment compared to those who had cleared HCV in the past following IFN-based therapies. RESULTS: Spontaneous clearance of the HCV infection was low in HIV-coinfected patients. One third of our HIV-HCV coinfected population had already been exposed to HCV therapy, but only a minority had achieved sustained HCV clearance. Half of patients with active HCV replication never exposed to IFN were not considered as appropriate candidates for HCV therapy. CONCLUSION: More flexible criteria would considerably increase the number of patients to be treated with IFN-based therapy. The majority of patients ready to initiate HCV therapy have a poor therapeutic profile.
Ivana Maida; Vincent Soriano; Belén Ramos; Pilar Ríos; Juan González-Lahoz; Marina Núñez
Related Documents :
9917576 - Hepatitis c: part i. routine serologic testing and diagnosis.
9918906 - Association of diabetes mellitus and chronic hepatitis c virus infection.
10330726 - Uncertain knowledge: a national survey of high school students' knowledge and beliefs a...
20462666 - Leukocytoclastic vasculitis and necrolytic acral erythema in patients with hepatitis c ...
25216106 - Stigma reduction in adolescents and young adults newly diagnosed with hiv: findings fro...
16299726 - Quantitative measurement of hepatitis b virus dna in different areas of hepatic lobules...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  HIV clinical trials     Volume:  6     ISSN:  1528-4336     ISO Abbreviation:  HIV Clin Trials     Publication Date:    2005 Nov-Dec
Date Detail:
Created Date:  2006-02-02     Completed Date:  2006-05-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100936377     Medline TA:  HIV Clin Trials     Country:  United States    
Other Details:
Languages:  eng     Pagination:  329-36     Citation Subset:  IM    
Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alanine Transaminase / blood
Antiviral Agents / therapeutic use*
Cross-Sectional Studies
HIV Infections / virology*
HIV-1 / growth & development*
Hepacivirus / genetics,  growth & development*
Hepatitis B Surface Antigens / blood
Hepatitis C, Chronic / blood,  drug therapy,  virology*
Interferon Alfa-2a / therapeutic use*
Middle Aged
Polyethylene Glycols / therapeutic use*
RNA, Viral / blood
Retrospective Studies
Ribavirin / therapeutic use
Reg. No./Substance:
0/Antiviral Agents; 0/Hepatitis B Surface Antigens; 0/Polyethylene Glycols; 0/RNA, Viral; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a; EC Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efa...
Next Document:  Changes in body fat measured by DEXA in patients taking different formulations of stavudine.